Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau, C.; Delord, J. P.; Goncalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Tredan, O.; Massiani, M. A.; Mauborgne, C.; Armanet, S.; Servant, N.; Bieche, I.; Bernard, V.; Gentien, D.; Jezequel, P.; Attignon, V.; Boyault, S.; Vincent-Salomon, A.; Servois, V.; Sablin, M. P.; Kamal, M.; Paoletti, X.; investigators, Shiva. Lancet Oncol. 2015; 1324-34: p.1324-34. doi:10.1016/S1470-2045(15)00188-6 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.

Article